- Home
- CHRS vs GAIA Comparison
CHRS vs GAIA Comparison
Compare CHRS & GAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- GAIA
- Stock Information
- Founded
- CHRS 2010
- GAIA 1988
- Country
- CHRS United States
- GAIA United States
- Employees
- CHRS N/A
- GAIA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- GAIA Movies/Entertainment
- Sector
- CHRS Health Care
- GAIA Consumer Discretionary
- Exchange
- CHRS Nasdaq
- GAIA Nasdaq
- Market Cap
- CHRS 112.5M
- GAIA 118.1M
- IPO Year
- CHRS 2014
- GAIA 1999
- Fundamental
- Price
- CHRS $0.76
- GAIA $4.31
- Analyst Decision
- CHRS Strong Buy
- GAIA Strong Buy
- Analyst Count
- CHRS 4
- GAIA 2
- Target Price
- CHRS $5.26
- GAIA $8.00
- AVG Volume (30 Days)
- CHRS 1.7M
- GAIA 69.9K
- Earning Date
- CHRS 05-12-2025
- GAIA 05-12-2025
- Dividend Yield
- CHRS N/A
- GAIA N/A
- EPS Growth
- CHRS N/A
- GAIA N/A
- EPS
- CHRS N/A
- GAIA N/A
- Revenue
- CHRS $272,251,000.00
- GAIA $92,889,000.00
- Revenue This Year
- CHRS N/A
- GAIA $14.66
- Revenue Next Year
- CHRS N/A
- GAIA $16.14
- P/E Ratio
- CHRS N/A
- GAIA N/A
- Revenue Growth
- CHRS 19.87
- GAIA 13.15
- 52 Week Low
- CHRS $0.66
- GAIA $2.93
- 52 Week High
- CHRS $2.43
- GAIA $6.53
- Technical
- Relative Strength Index (RSI)
- CHRS 36.67
- GAIA 45.00
- Support Level
- CHRS $0.71
- GAIA $4.22
- Resistance Level
- CHRS $1.06
- GAIA $5.32
- Average True Range (ATR)
- CHRS 0.08
- GAIA 0.36
- MACD
- CHRS -0.03
- GAIA -0.12
- Stochastic Oscillator
- CHRS 12.44
- GAIA 6.87
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About GAIA Gaia Inc.
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. Geographically, it derives a majority of its revenue from the United States and also has an International presence.